Eli Lilly and Company opens new technology and innovation site in Hyderabad, India to enhance global operations.

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Lilly has already taken 100 professionals at the Hyderabad facility and plans to expand the headcount to 1,500 over the next ...

Eli Lilly and Company has opened a technology and innovation center in, India. This strategic hub, covering 2.2 lakh sqft, ...

Telangana Chief Minister A. Revanth Reddy inaugurated US pharma major Eli Lilly’s Global Capability Centre (GCC) in Hyderabad ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...